Rescue of synthetic analogs of genomic RNA and replicative-intermediate RNA of human parainfluenza virus type 3.

Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A (1995) 9.08

Infectious rabies viruses from cloned cDNA. EMBO J (1994) 8.35

Rescue of measles viruses from cloned DNA. EMBO J (1995) 7.87

Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc Natl Acad Sci U S A (1995) 6.95

Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J Virol (1999) 4.32

Rescue of synthetic genomic RNA analogs of rabies virus by plasmid-encoded proteins. J Virol (1994) 4.10

RNA replication by respiratory syncytial virus (RSV) is directed by the N, P, and L proteins; transcription also occurs under these conditions but requires RSV superinfection for efficient synthesis of full-length mRNA. J Virol (1995) 3.76

Functional cDNA clones of the human respiratory syncytial (RS) virus N, P, and L proteins support replication of RS virus genomic RNA analogs and define minimal trans-acting requirements for RNA replication. J Virol (1995) 3.48

NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs. J Virol (2000) 2.74

Negative-strand RNA viruses: genetic engineering and applications. Proc Natl Acad Sci U S A (1996) 2.47

An infectious clone of human parainfluenza virus type 3. J Virol (1997) 2.28

RNA replication by a respiratory syncytial virus RNA analog does not obey the rule of six and retains a nonviral trinucleotide extension at the leader end. J Virol (1996) 1.86

Regulation of RNA synthesis by the genomic termini of vesicular stomatitis virus: identification of distinct sequences essential for transcription but not replication. J Virol (1999) 1.58

Replication and amplification of novel vesicular stomatitis virus minigenomes encoding viral structural proteins. J Virol (1995) 1.55

The activity of Sendai virus genomic and antigenomic promoters requires a second element past the leader template regions: a motif (GNNNNN)3 is essential for replication. J Virol (1998) 1.52

Virus promoters determine interference by defective RNAs: selective amplification of mini-RNA vectors and rescue from cDNA by a 3' copy-back ambisense rabies virus. J Virol (1999) 1.40

A functional antigenomic promoter for the paramyxovirus simian virus 5 requires proper spacing between an essential internal segment and the 3' terminus. J Virol (1998) 1.27

Rescue of synthetic minireplicons establishes the absence of the NS1 and NS2 genes from avian pneumovirus. J Virol (1997) 1.15

Ambisense gene expression from recombinant rabies virus: random packaging of positive- and negative-strand ribonucleoprotein complexes into rabies virions. J Virol (1997) 1.15

The 5' terminal trailer region of vesicular stomatitis virus contains a position-dependent cis-acting signal for assembly of RNA into infectious particles. J Virol (1999) 0.99

Temperature-sensitive phenotype of the human parainfluenza virus type 3 candidate vaccine strain (cp45) correlates with a defect in the L gene. J Virol (1996) 0.88

Positive strands to the rescue again: a segmented negative-strand RNA virus derived from cloned cDNAs. Proc Natl Acad Sci U S A (1996) 0.86

Mutations within noncoding terminal sequences of model RNAs of Sendai virus: influence on reporter gene expression. J Virol (1995) 0.84

Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol (1982) 116.75

Amplification, expression, and packaging of foreign gene by influenza virus. Cell (1989) 11.21

Introduction of site-specific mutations into the genome of influenza virus. Proc Natl Acad Sci U S A (1990) 7.68

Infectious defective interfering particles of VSV from transcripts of a cDNA clone. Cell (1992) 5.72

Rescue of synthetic analogs of respiratory syncytial virus genomic RNA and effect of truncations and mutations on the expression of a foreign reporter gene. Proc Natl Acad Sci U S A (1991) 4.35

High-efficiency formation of influenza virus transfectants. J Virol (1991) 4.34

The polyadenylation signal of influenza virus RNA involves a stretch of uridines followed by the RNA duplex of the panhandle structure. J Virol (1991) 3.85

Rescue of a foreign gene by Sendai virus. Proc Natl Acad Sci U S A (1991) 3.85

A new method for reconstituting influenza polymerase and RNA in vitro: a study of the promoter elements for cRNA and vRNA synthesis in vitro and viral rescue in vivo. Virology (1992) 2.85

Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol (1989) 2.59

An influenza A virus containing influenza B virus 5' and 3' noncoding regions on the neuraminidase gene is attenuated in mice. Proc Natl Acad Sci U S A (1991) 2.55

Attenuation of influenza A virus by insertion of a foreign epitope into the neuraminidase. J Virol (1992) 2.37

Distinct subunits of the ribonucleoprotein of influenza virus. J Mol Biol (1969) 2.26

In vivo analysis of the promoter structure of the influenza virus RNA genome using a transfection system with an engineered RNA. Proc Natl Acad Sci U S A (1991) 2.03

Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus. Virology (1985) 1.90

Influenza A virus transfectants with chimeric hemagglutinins containing epitopes from different subtypes. J Virol (1992) 1.88

Rescue of a Sendai virus DI genome by other parainfluenza viruses: implications for genome replication. Virology (1991) 1.45

Some properties of influenza virus nucleocapsids. J Virol (1969) 1.41

In vitro assembly of a functional nucleocapsid from the negative-stranded genome RNA of a defective interfering particle of vesicular stomatitis virus. Proc Natl Acad Sci U S A (1988) 1.31

Molecular cloning and sequence analysis of the human parainfluenza 3 virus gene encoding the L protein. Virology (1988) 1.16

Nucleotide sequences that affect replicative and transcriptional efficiencies of Sendai virus deletion mutants. J Virol (1986) 0.99

3'-Terminal sequence of human parainfluenza virus 3 genomic RNA. Nucleic Acids Res (1986) 0.96

Complete sequence of the major nucleocapsid protein gene of human parainfluenza type 3 virus: comparison with other negative strand viruses. J Gen Virol (1986) 0.91

Paradoxical effects of Sendai virus DI RNA size on survival: inefficient envelopment of small nucleocapsids. Virology (1988) 0.91

Defective interfering particles of human parainfluenza virus type 3 are associated with persistent infection in cell culture. Virology (1991) 0.89

Defective interfering particles of human parainfluenza virus 3. Virology (1987) 0.86

The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci U S A (1987) 4.93

Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci U S A (1986) 4.14

Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein. Proc Natl Acad Sci U S A (1985) 3.93

RNA replication by respiratory syncytial virus (RSV) is directed by the N, P, and L proteins; transcription also occurs under these conditions but requires RSV superinfection for efficient synthesis of full-length mRNA. J Virol (1995) 3.76

Nucleotide sequence of the gene encoding the fusion (F) glycoprotein of human respiratory syncytial virus. Proc Natl Acad Sci U S A (1984) 3.42

cDNA cloning and transcriptional mapping of nine polyadenylylated RNAs encoded by the genome of human respiratory syncytial virus. Proc Natl Acad Sci U S A (1983) 3.05

Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J Virol (1997) 2.82

Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J Virol (1999) 2.80

Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J Virol (2000) 2.75

Identification of a tenth mRNA of respiratory syncytial virus and assignment of polypeptides to the 10 viral genes. J Virol (1984) 2.45

Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology (2001) 2.38

Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order. Proc Natl Acad Sci U S A (1986) 2.36

Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection. Virology (2000) 2.28

Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J Virol (1987) 2.26

Conserved epitopes on the hemagglutinin-neuraminidase proteins of human and bovine parainfluenza type 3 viruses: nucleotide sequence analysis of variants selected with monoclonal antibodies. J Virol (1986) 2.19

Recovery of infectious human parainfluenza virus type 3 from cDNA. Virology (1997) 2.17

The envelope-associated 22K protein of human respiratory syncytial virus: nucleotide sequence of the mRNA and a related polytranscript. J Virol (1985) 2.15

Fusion glycoprotein of human parainfluenza virus type 3: nucleotide sequence of the gene, direct identification of the cleavage-activation site, and comparison with other paramyxoviruses. Virology (1986) 2.14

Role of the M2-1 transcription antitermination protein of respiratory syncytial virus in sequential transcription. J Virol (1999) 2.11

Altered growth characteristics of recombinant respiratory syncytial viruses which do not produce NS2 protein. J Virol (1999) 2.06

Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J Virol (1991) 2.05

The NS1 protein of human respiratory syncytial virus is a potent inhibitor of minigenome transcription and RNA replication. J Virol (1998) 2.02

The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc Natl Acad Sci U S A (1999) 1.98

Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J Virol (2000) 1.97

Effects of mutations in the gene-start and gene-end sequence motifs on transcription of monocistronic and dicistronic minigenomes of respiratory syncytial virus. J Virol (1996) 1.95

Identification of the respiratory syncytial virus proteins required for formation and passage of helper-dependent infectious particles. J Virol (1998) 1.95

Transcriptional map for Newcastle disease virus. J Virol (1980) 1.90

Increased expression of the N protein of respiratory syncytial virus stimulates minigenome replication but does not alter the balance between the synthesis of mRNA and antigenome. Virology (1997) 1.90

An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res (1994) 1.87

Sequence analysis of the polymerase L gene of human respiratory syncytial virus and predicted phylogeny of nonsegmented negative-strand viruses. Virology (1991) 1.87

RNA replication by a respiratory syncytial virus RNA analog does not obey the rule of six and retains a nonviral trinucleotide extension at the leader end. J Virol (1996) 1.86

Expression of the major glycoprotein G of human respiratory syncytial virus from recombinant vaccinia virus vectors. Proc Natl Acad Sci U S A (1986) 1.85

Newcastle disease virus stimulates the cellular accumulation of stress (heat shock) mRNAs and proteins. J Virol (1982) 1.83

Characterization of the 10 proteins of human respiratory syncytial virus: identification of a fourth envelope-associated protein. Virus Res (1985) 1.82

Nucleotide sequences of the 3' leader and 5' trailer regions of human respiratory syncytial virus genomic RNA. Virology (1991) 1.80

Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV. Vaccine (1992) 1.79

Human parainfluenza virus type 3: messenger RNAs, polypeptide coding assignments, intergenic sequences, and genetic map. J Virol (1986) 1.78

Transcriptional mapping of human respiratory syncytial virus. J Virol (1984) 1.76

The structurally diverse intergenic regions of respiratory syncytial virus do not modulate sequential transcription by a dicistronic minigenome. J Virol (1996) 1.72

The 1B (NS2), 1C (NS1) and N proteins of human respiratory syncytial virus (RSV) of antigenic subgroups A and B: sequence conservation and divergence within RSV genomic RNA. J Gen Virol (1989) 1.71

Gene overlap and site-specific attenuation of transcription of the viral polymerase L gene of human respiratory syncytial virus. Proc Natl Acad Sci U S A (1987) 1.69

Synthesis and processing of Sindbis virus nonstructural proteins in vitro. Virology (1982) 1.68

Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity. J Virol (1987) 1.67

Coding assignments of the five smaller mRNAs of Newcastle disease virus. J Virol (1982) 1.67

Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J Virol (1998) 1.66

Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene. J Virol (1996) 1.62

Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate. Virology (1996) 1.60

Analysis of the gene start and gene end signals of human respiratory syncytial virus: quasi-templated initiation at position 1 of the encoded mRNA. J Virol (1997) 1.57

Transcription and translation of Newcastle disease virus mRNA's in vitro. J Virol (1978) 1.56

Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates. Virology (1999) 1.54

Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine. J Virol (2000) 1.52

The fusion glycoproteins of human respiratory syncytial virus of subgroups A and B: sequence conservation provides a structural basis for antigenic relatedness. J Gen Virol (1988) 1.50

Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins. J Virol (1990) 1.50

The A and B subgroups of human respiratory syncytial virus: comparison of intergenic and gene-overlap sequences. J Gen Virol (1988) 1.48

Minimum protein requirements for transcription and RNA replication of a minigenome of human parainfluenza virus type 3 and evaluation of the rule of six. Virology (1997) 1.48

A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes. Virology (1998) 1.47

A cold-passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes. Virology (1995) 1.46

Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus. J Virol (1995) 1.45

Virus replication in engineered human cells that do not respond to interferons. J Virol (2003) 1.44

Sequence analysis of the P and C protein genes of human parainfluenza virus type 3: patterns of amino acid sequence homology among paramyxovirus proteins. J Gen Virol (1986) 1.43

Nucleotide sequences of the 1B and 1C nonstructural protein mRNAs of human respiratory syncytial virus. Virology (1985) 1.35

The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein. J Virol (1997) 1.33

Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine. J Virol (1999) 1.33

A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine (1993) 1.33

The 1A protein of respiratory syncytial virus is an integral membrane protein present as multiple, structurally distinct species. J Virol (1989) 1.32

Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene. Virus Genes (1996) 1.32

Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies. J Virol (1992) 1.31

Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J Virol (2000) 1.31

Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells. J Virol (2001) 1.31

Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J Virol (1999) 1.30

Model for polymerase access to the overlapped L gene of respiratory syncytial virus. J Virol (1999) 1.27

Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature-sensitive and attenuation phenotypes. Virology (2000) 1.24

Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses. Virus Res (1988) 1.24

Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J Virol (2001) 1.24

Mutations in the 5' trailer region of a respiratory syncytial virus minigenome which limit RNA replication to one step. J Virol (2000) 1.23

Processing, surface expression, and immunogenicity of carboxy-terminally truncated mutants of G protein of human respiratory syncytial virus. J Virol (1989) 1.21

The 1A protein gene of human respiratory syncytial virus: nucleotide sequence of the mRNA and a related polycistronic transcript. Virology (1985) 1.20

Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy. J Virol (2000) 1.19

Sequence determination and molecular analysis of two strains of bovine parainfluenza virus type 3 that are attenuated for primates. Virus Genes (2000) 1.18

Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes. J Virol (1998) 1.18

Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1. J Virol (1998) 1.17

Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization. Pediatrics (1992) 1.15

Cloning and nucleotide sequence of Newcastle disease virus hemagglutinin-neuraminidase mRNA: identification of a putative sialic acid binding site. Virology (1987) 1.13

Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses. J Virol (1988) 1.12

Cellular localization of the molecular forms of acetylcholinesterase in rat diaphragm. J Biol Chem (1982) 1.11

A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3. Vaccine (2000) 1.11

Functional analysis of the genomic and antigenomic promoters of human respiratory syncytial virus. J Virol (2000) 1.11

Correct sequence for the major nucleocapsid protein mRNA of respiratory syncytial virus. Virology (1985) 1.10

The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations. Vaccine (1999) 1.09

A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates. J Virol (2000) 1.07

Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates. J Virol (2000) 1.05

Intracellular amplification and expression of a synthetic analog of rotavirus genomic RNA bearing a foreign marker gene: mapping cis-acting nucleotides in the 3'-noncoding region. Proc Natl Acad Sci U S A (1992) 1.04

Interferon gamma expressed by a recombinant respiratory syncytial virus attenuates virus replication in mice without compromising immunogenicity. Proc Natl Acad Sci U S A (1999) 1.04

Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts. Vaccine (1999) 1.02

Expression of biologically active and antigenically authentic parainfluenza type 3 virus hemagglutinin-neuraminidase glycoprotein by a recombinant baculovirus. Virology (1987) 1.01

Rescue of a bovine respiratory syncytial virus genomic RNA analog by bovine, human and ovine respiratory syncytial viruses confirms the "functional integrity" and "cross-recognition" of BRSV cis-acting elements by HRSV and ORSV. Arch Virol (1999) 0.99

Respiratory syncytial virus can tolerate an intergenic sequence of at least 160 nucleotides with little effect on transcription or replication in vitro and in vivo. J Virol (2000) 0.99

Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation. Virology (1999) 0.98

RhoA is activated during respiratory syncytial virus infection. Virology (2001) 0.98

Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates. J Virol (1999) 0.97